-
公开(公告)号:US08263351B2
公开(公告)日:2012-09-11
申请号:US13024963
申请日:2011-02-10
申请人: George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
发明人: George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
IPC分类号: G01N33/53
CPC分类号: G01N33/6893 , G01N2800/325
摘要: The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF).
摘要翻译: 本发明提供了用于定量生物流体样品中循环血型糖蛋白的测定。 通过该测定测量的循环血型糖蛋白是用于充血性心力衰竭(CHF)的截短的血型糖蛋白诊断。
-
公开(公告)号:US07741286B2
公开(公告)日:2010-06-22
申请号:US11350703
申请日:2006-02-08
申请人: Dominique P. Bridon , Michele Rasamoelisolo , Karen Thibaudeau , Xicai Huang , Richard Beliveau
发明人: Dominique P. Bridon , Michele Rasamoelisolo , Karen Thibaudeau , Xicai Huang , Richard Beliveau
IPC分类号: A61K38/00
CPC分类号: C07K14/005 , A61K38/00 , C07K14/605 , C12N2740/16122
摘要: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.
摘要翻译: 公开了修饰的抗血管生成肽。 修饰的肽能够形成肽酶稳定的抗血管生成肽。 修饰的抗血管生成肽,特别是修饰的三环5肽能够与血液蛋白形成缀合物。 通过将肽与反应性官能团与血液蛋白结合,由抗血管生成肽,特别是kringle 5肽制备缀合物。 缀合物可以在体内或离体形成。 向患者施用共轭物以提供抗血管生成作用。
-
公开(公告)号:US20050100964A1
公开(公告)日:2005-05-12
申请号:US10706599
申请日:2003-11-11
申请人: George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
发明人: George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
IPC分类号: G01N33/53 , G01N33/543 , G01N33/577 , G01N33/68
CPC分类号: G01N33/6893 , G01N2800/325
摘要: The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF).
摘要翻译: 本发明提供了用于定量生物流体样品中循环血型糖蛋白的测定。 通过该测定测量的循环血型糖蛋白是用于充血性心力衰竭(CHF)的截短的血型糖蛋白诊断。
-
公开(公告)号:US20110071082A1
公开(公告)日:2011-03-24
申请号:US12759153
申请日:2010-04-13
申请人: Dominique P. Bridon , Michele Rasamoelisolo , Karen Thibaudeau , Xicai Huang , Richard Beliveau
发明人: Dominique P. Bridon , Michele Rasamoelisolo , Karen Thibaudeau , Xicai Huang , Richard Beliveau
CPC分类号: C07K14/005 , A61K38/00 , C07K14/605 , C12N2740/16122
摘要: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.
摘要翻译: 公开了修饰的抗血管生成肽。 修饰的肽能够形成肽酶稳定的抗血管生成肽。 修饰的抗血管生成肽,特别是修饰的三环5肽能够与血液蛋白形成缀合物。 通过将肽与反应性官能团与血液蛋白结合,由抗血管生成肽,特别是kringle 5肽制备缀合物。 缀合物可以在体内或离体形成。 向患者施用共轭物以提供抗血管生成作用。
-
公开(公告)号:US20090068676A1
公开(公告)日:2009-03-12
申请号:US11786885
申请日:2007-04-13
申请人: George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
发明人: George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
IPC分类号: G01N33/53
CPC分类号: G01N33/6893 , G01N2800/325
摘要: The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF).
摘要翻译: 本发明提供了用于定量生物流体样品中循环血型糖蛋白的测定。 通过该测定测量的循环血型糖蛋白是用于充血性心力衰竭(CHF)的截短的血型糖蛋白诊断。
-
公开(公告)号:US20110183436A1
公开(公告)日:2011-07-28
申请号:US13024963
申请日:2011-02-10
申请人: George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
发明人: George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
IPC分类号: G01N33/53
CPC分类号: G01N33/6893 , G01N2800/325
摘要: The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF).
摘要翻译: 本发明提供了用于定量生物流体样品中循环血型糖蛋白的测定。 通过该测定测量的循环血型糖蛋白是用于充血性心力衰竭(CHF)的截短的血型糖蛋白诊断。
-
公开(公告)号:US07144854B1
公开(公告)日:2006-12-05
申请号:US09657431
申请日:2000-09-07
申请人: Dominique P. Bridon , Michele Rasamoelisolo , Karen Thibaudeau , Xicai Huang , Richard Beliveau
发明人: Dominique P. Bridon , Michele Rasamoelisolo , Karen Thibaudeau , Xicai Huang , Richard Beliveau
IPC分类号: A61K38/00
CPC分类号: C12N9/6408
摘要: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.
摘要翻译: 公开了修饰的抗血管生成肽。 修饰的肽能够形成肽酶稳定的抗血管生成肽。 修饰的抗血管生成肽,特别是修饰的三环5肽能够与血液蛋白形成缀合物。 通过将肽与反应性官能团与血液蛋白结合,由抗血管生成肽,特别是kringle 5肽制备缀合物。 缀合物可以在体内或离体形成。 向患者施用共轭物以提供抗血管生成作用。
-
公开(公告)号:US20060135428A1
公开(公告)日:2006-06-22
申请号:US11350703
申请日:2006-02-08
CPC分类号: C07K14/005 , A61K38/00 , C07K14/605 , C12N2740/16122
摘要: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.
-
-
-
-
-
-
-